Archive for Cancer research
Reports of an experimental drug that slowed advanced breast cancer in a clinical trial have stirred excitement at a national research meeting and breathed new life into a cancer-fighting strategy that had seemed to falter.
It’s been suggested that regular use of talcum powder products in the genital area might increase the possibility of ovarian cancer. In theory, particles of talc could travel through the reproductive tract to the ovaries and cause cancer. Research on this potential link has yielded mixed findings, with some studies finding a small increase in risk.
A young woman in her prime, with a full life and meaningful career, does not expect a cancer diagnosis. But that is what happened to 34-year-old Erin, who received the news when she was in Paris with her mother and sister, on a long-awaited trip to celebrate Mother’s Day. Read more
By Tom Ulrich
One of the hot trends in drug discovery could be called drug re-discovery: finding new uses for drugs that have already received FDA approval for a different indication.
It’s an approach that allows researchers and clinicians to rapidly test potential treatments for rare or difficult-to-treat conditions. Because the drug’s safety profile is already known, much of the preclinical and early clinical work that goes into developing a drug can be bypassed.
The Food and Drug Administration’s recent approval of the drug ibrutinib offers a major new option for patients with chronic lymphocytic leukemia (CLL) who tried at least one prior therapy, physicians say.
Cancers of the vulva – the external portion of the female genitals – are diagnosed in approximately 4,700 women in the United States each year. While many patients can be cured by a combination of surgery, chemotherapy, and radiation therapy, others – particularly those whose cancer has metastasized to other parts of the body – often don’t fare as well.
As one of the rarer forms of gynecologic cancer, vulvar cancer hasn’t attracted as much research funding as other forms. Still, several efforts are under way to make treatment options more effective, according to Neil Horowitz, MD, a vulvar cancer expert at the Susan F. Smith Center for Women’s Cancers at Dana-Farber.
A Food and Drug Administration (FDA) panel has recommended that a DNA test should be the primary screening tool for cervical cancer, rather than the traditional Pap smear. The DNA test detects the DNA of human papillomavirus (HPV), the sexually transmitted infection that causes almost all cases of cervical cancer.
“This is an important step forward for cervical cancer screening,” says Alexi Wright, MD, MPH, a medical oncologist in the Susan F. Smith Center for Women’s Cancers at Dana-Farber. Specifically, the DNA test screens for HPV-16 and HPV-18, the two highest-risk HPV strains, as well as 12 other high-risk HPV types, using a blood sample.
The number of deaths from breast cancer has dropped over the past decade in the United States, but around the world, especially in less-developed countries, the number is rising. A report from the World Health Organization (WHO) in December 2013 said 522,000 women died from breast cancer in 2012 – a 14 percent increase compared with 2008.
Outcomes are gradually improving for patients who suffer from graft-versus-host disease (GVHD), one of the most serious complications of stem cell transplantation, and researchers are optimistic that further advances may be on the way.